XVIVO Xvivo Perfusion AB (publ)

19.28USD195.90 SEK · STO-0.66%Mkt Cap: 607.38M USDP/E: 47.32

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates…

Institutional holders10 on file

Key Statistics

Company
Market Cap607.38M USD
Enterprise Value588.42M USD
Revenue (TTM)94.36M USD
Gross Profit59.01M USD
Net Income (TTM)2.48M USD
Revenue/Share3.00 USD
Last Price19.28 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees207
CountrySE
SectorHealthcare
IndustryMedical Devices
ISINSE0004840718
Valuation
P/E (Trailing)47.32
P/E (Forward)33.15
PEG—
EV/EBITDA33.41
EV/Revenue6.24
P/S6.44
P/B2.72
EPS (TTM)0.41 USD
EPS (Forward)0.58 USD
52W Range
15.7623% of range30.99
52W High30.99 USD
52W Low15.76 USD
Profitability
Gross Margin73.81%
Oper. Margin13.33%
EBITDA Margin18.67%
Profit Margin3.10%
ROE1.19%
ROA1.06%
ROIC3.09%
ROCE4.09%
Growth
Revenue Growth33.50%
Earnings Growth928.10%
Cash Flow & Leverage
Operating CF9.95M USD
CapEx (TTM)24.89M USD
FCF Margin0.26%
FCF Yield0.04%
Net Debt-18.96M USD
Net Debt/EBITDA-1.08
Net Debt/FCF-76.65
Balance Sheet
Debt/Equity0.06
Current Ratio3.92
Quick Ratio2.69
Book Value/Sh7.08 USD
Cash/Share0.98 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)29.92 USD
Upside (mean)+55.2%
Target Range25.59 USD – 35.43 USD
25.59+55.2% to mean35.43
# Analysts5
Ownership
Shares Out.31.50M
Float25.13M
Insiders8.33%
Institutions60.78%
Technical
SMA 5021.61 (-10.8%)
SMA 20024.00 (-19.7%)
Beta1.47
S&P 52W Chg12.00%
Avg Vol (30d)81.51K
Avg Vol (10d)84.49K
Technical Indicators
RSI (14)37.5
MACD-6.1447
MACD Signal-6.7430
MACD Hist.+0.5982
BB Upper20.53 USD
BB Middle19.80 USD
BB Lower19.08 USD
BB Width7.32%
ATR (14)0.7435 USD
Vol Ratio (20d)0.54x

About Xvivo Perfusion (STO: XVIVO)

›

Xvivo Perfusion (STO: XVIVO) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 207 employees.

The shares were at 195.90 SEK on 19 November 2026, up 15.2% over 52 weeks. Its 52-week range is 160.10 SEK to 314.80 SEK: the price is 37.8% below the high and 22.4% above the low.

At a market capitalisation of 6.17B SEK, it trades at 47.3 times trailing earnings and 33.1 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a premium of 85% for XVIVO.

Xvivo Perfusion reports return on equity of 1.2%, an operating margin of 13.3% and revenue up 33.5% year over year.

It holds more cash than debt, a net cash position of 192.63M SEK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 5 analysts cover the stock; their mean price target of 304.00 SEK is 55.2% above the current price. The next earnings report is expected on 28 January 2027.